Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R, Catacchio I, Berardi S, De Luisi A, Caivano A, Piccoli C, Ruggieri V, Frassanito MA, Ribatti D, Nico B, Annese T, Ruggieri S, Guarini A, Minoia C, Ditonno P, Angelucci E, Derudas D, Moschetta M, Dammacco F, Vacca A. Ria R, et al. Among authors: catacchio i. Clin Cancer Res. 2014 Feb 15;20(4):847-58. doi: 10.1158/1078-0432.CCR-13-1950. Epub 2013 Dec 2. Clin Cancer Res. 2014. PMID: 24297864
A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, Maffia M, Latorre D, Rizzello A, Zito A, Ditonno P, Maiorano E, Ribatti D, Vacca A. Ferrucci A, et al. Among authors: catacchio i. Clin Cancer Res. 2014 Nov 15;20(22):5796-807. doi: 10.1158/1078-0432.CCR-14-0847. Epub 2014 Sep 11. Clin Cancer Res. 2014. PMID: 25212607
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
Berardi S, Caivano A, Ria R, Nico B, Savino R, Terracciano R, De Tullio G, Ferrucci A, De Luisi A, Moschetta M, Mangialardi G, Catacchio I, Basile A, Guarini A, Zito A, Ditonno P, Musto P, Dammacco F, Ribatti D, Vacca A. Berardi S, et al. Among authors: catacchio i. Oncogene. 2012 May 3;31(18):2258-69. doi: 10.1038/onc.2011.412. Epub 2011 Oct 3. Oncogene. 2012. PMID: 21963844
Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.
Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, Racanelli V, Catacchio I, Berardi S, Basile A, Menu E, Ruggieri S, Nico B, Ribatti D, Fumarulo R, Dammacco F, Vanderkerken K, Vacca A. Frassanito MA, et al. Among authors: catacchio i. Leukemia. 2014 Apr;28(4):904-16. doi: 10.1038/leu.2013.254. Epub 2013 Sep 2. Leukemia. 2014. PMID: 23995611
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA, De Veirman K, Desantis V, Di Marzo L, Vergara D, Ruggieri S, Annese T, Nico B, Menu E, Catacchio I, Ria R, Racanelli V, Maffia M, Angelucci E, Derudas D, Fumarulo R, Dammacco F, Ribatti D, Vanderkerken K, Vacca A. Frassanito MA, et al. Among authors: catacchio i. Leukemia. 2016 Mar;30(3):640-8. doi: 10.1038/leu.2015.289. Epub 2015 Oct 21. Leukemia. 2016. PMID: 26487273
Could multiple myeloma VEGF modify the systemic microcirculation?
Cicco S, Ditonno P, Reale A, Savino S, Castrovilli A, Catacchio I, Ria R, Vacca A. Cicco S, et al. Among authors: catacchio i. Adv Exp Med Biol. 2012;737:155-60. doi: 10.1007/978-1-4614-1566-4_23. Adv Exp Med Biol. 2012. PMID: 22259096 No abstract available.
15 results